Linked Life Data

16530853

Source:http://linkedlifedata.com/resource/pubmed/id/16530853

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2006-4-17
pubmed:abstractText
Purinergic signalling has been implicated in many biological processes, and ATP and other extracellular nucleotides might have therapeutic potential in the treatment of cancer by signalling through P2 receptors. Different P2 receptor subtypes have been identified in a variety of different cancer types, in both primary samples of human cancer tissue and cell lines. Recent evidence suggests that different receptor subtypes mediate different pathophysiological functions such as proliferation, differentiation and apoptosis. In vivo studies of the use of ATP suggest that it can decrease the rate of cancer growth, and the first clinical trials have been undertaken. Thus, agents acting at P2 receptors might provide novel therapeutic tools in the treatment of cancer. In this article, background information about purinergic signalling and purinoceptor subtypes will be provided and then the proposed role of ATP in different cancers will be discussed in detail, including a discussion of in vivo studies and animal models, clinical trials and the specific P2 receptor subtypes involved.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0165-6147
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
211-7
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
P2 receptors and cancer.
pubmed:affiliation
Autonomic Neuroscience Centre, Royal Free and University College Medical School, Rowland Hill Street, London, UK, NW3 2PF.
pubmed:publicationType
Journal Article, Review